An exploration of women's experience of taking part in a randomized controlled trial of a diagnostic test during pregnancy: A qualitative study by Hayes-Ryan, Deirdre et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title An exploration of women's experience of taking part in a randomized
controlled trial of a diagnostic test during pregnancy: A qualitative study
Author(s) Hayes-Ryan, Deirdre; Meaney, Sarah; Nolan, Caroline; O'Donoghue,
Keelin
Publication date 2019-10-02
Original citation Hayes-Ryan, D., Meaney, S., Nolan, C. and O’Donoghue, K. 'An
exploration of women's experience of taking part in a randomized
controlled trial of a diagnostic test during pregnancy: A qualitative
study', Health Expectations, in press. (9pp.) doi: 10.1111/hex.12969
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10.1111/hex.12969
Access to the full text of the published version may require a
subscription.
Rights ©2019 The Authors. Health Expectations published by John Wiley
& Sons Ltd. This is an open access article under the terms of the
Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited
http://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/9322
Downloaded on 2020-06-06T01:25:01Z
Health Expectations. 2019;00:1–9.	 	 	 | 	1wileyonlinelibrary.com/journal/hex
 
Received:	25	June	2019  |  Revised:	12	August	2019  |  Accepted:	30	August	2019
DOI: 10.1111/hex.12969  
O R I G I N A L  R E S E A R C H  P A P E R
An exploration of women's experience of taking part in 
a randomized controlled trial of a diagnostic test during 
pregnancy: A qualitative study
Deirdre Hayes‐Ryan MB, BCh, BAO, MRCOG, MRCPI, Clinical Research Fellow1,2  |   
Sarah Meaney BA, MA, PhD, Postdoctoral Researcher3 |   Caroline Nolan BSc, Research 
Assistant1 |   Keelin O’Donoghue MB, BCh, BAO, PhD, FRCOG, Principal Investigator, 
Consultant Obstetrician and Senior Lecturer1,2
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided	the	original	work	is	properly	cited.
©	2019	The	Authors.	Health Expectations	published	by	John	Wiley	&	Sons	Ltd.
1The	Irish	Centre	for	Fetal	and	Neonatal	
Translational	Research	(INFANT),	University	
College	Cork,	Cork,	Ireland
2Cork	University	Maternity	Hospital	
(CUMH),	Cork,	Ireland
3National	Perinatal	Epidemiology	
Centre,	University	College	Cork,	Ireland
Correspondence
Deirdre	Hayes‐Ryan,	INFANT	Research	
Centre,	CUMH,	Cork,	Ireland.
Email:	Deirdre.hayesryan@ucc.ie
Funding informationNo	specific	funding	was	
received	to	conduct	this	project.
Abstract
Objective: To	explore	pregnant	women's	views	of	participation	in	a	clinical	research	
trial	while	pregnant.
Design: Prospective	 nested	 qualitative	 cohort	 study	 embedded	within	 a	 national,	
multi‐site	randomized	controlled	trial	of	a	diagnostic	test	for	preeclampsia:	Placental	
Growth	Factor.	One‐to‐one	 in‐depth	 semi‐structured	 interviews	were	undertaken	
with	19	women	who	had	recently	participated	in	the	trial	at	a	single	recruiting	site.	The	
interviews	were	conducted	in	private,	recorded	digitally	and	transcribed	verbatim.
Setting: Single	tertiary	maternity	hospital	currently	recruiting	eligible	women	onto	an	
on‐going	randomized	controlled	trial	(NCT	02881073).
Participants: Women	who	had	participated	in	the	PARROT	Ireland	randomized	con‐
trolled	trial	during	their	recent	pregnancy.
Methods: Thematic	analysis	was	utilized.	Each	line	of	the	transcribed	interviews	was	
coded	into	a	category	by	two	researchers.	The	resultant	categories	were	reviewed,	
and	those	with	similarities	were	pooled	allowing	the	development	of	themes.
Main Outcome Measures: Women's	opinions	and	experience	of	participation	in	a	ran‐
domized	controlled	trial	of	an	interventional	diagnostic	test	during	their	pregnancy.
Results: Four	major	themes	were	identified	as	follows:	(a)	Understanding	of	preec‐
lampsia,	(b)	Motivators	for	clinical	trial	participation,	(c)	Barriers	to	decision	making	
and	(d)	Influence	of	PARROT	Ireland	on	pregnancy	experience.
Conclusions: Women	are	generally	 interested	and	positively	 inclined	to	participate	
in	research	during	pregnancy.	The	potential	of	risk	is	an	important	consideration	for	
eligible	pregnant	woman.	Information	and	support	by	both	researchers	and	clinicians	
are	paramount	in	aiding	women's	understanding	of	a	research	trial.
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1  | INTRODUC TION
A	randomized	controlled	trial	(RCT)	is	regarded	as	the	gold	standard	
when	 testing	efficacy	of	 any	new	drug,	 intervention	or	diagnostic	
test.1,2	The	use	of	drugs	such	as	thalidomide	and	diethylstilbestrol	
in	pregnant	women	has	had	long‐lasting	repercussions,	with	women	
of	 childbearing	age	 traditionally	being	excluded	 from	clinical	 trials	
owing	to	safety	concerns	and	fear	of	litigation.3,4	Nevertheless,	up	
to	74%	of	pregnant	women	take	at	least	one	mediation	for	chronic	or	
acute	conditions	while	the	use	of	prescription	medications	by	preg‐
nant	women	has	risen	by	more	than	60%	over	the	last	three	decades,	
with	most	of	these	drugs	being	used	off‐label.5,6	The	paucity	of	ev‐
idence	available	on	the	use	of	medications	in	pregnancy	means	that	
some	pregnant	women	may	not	be	receiving	optimal	treatment,	as	
clinicians	are	often	unsure	regarding	correct	dosage	due	to	the	phys‐
iological	and	metabolic	changes	that	occur	in	pregnancy.7,8	Further,	
lack	of	inclusion	of	women	in	clinical	trials	has	resulted	in	a	lack	of	
evidence‐based	 care	 for	 pregnant	 women.	 Interventions	 such	 as	
cardiotocography	and	foetal	fibronectin	testing	were	integrated	into	
clinical	practice	prior	to	robust	evidence	of	their	benefit.9	Once	use	
of	 such	 clinical	 interventions	 is	 established	within	 a	 system,	with‐
drawal	becomes	challenging.10
In	the	last	number	of	years,	concerns	have	arisen	over	the	eth‐
ics	of	actively	excluding	pregnant	women	from	clinical	trials.11‐14 In 
1993,	the	Food	and	Drug	Administration	(FDA)	lifted	its	ban	on	the	
testing	of	medicinal	products	in	women	and	the	National	Institute	
for	Health	(NIH)	legally	endorsed	the	inclusion	of	pregnant	women	
in	trials.15,16	Since	the	mid‐90s,	there	has	been	a	concerted	effort	
to	ensure	minorities,	such	as	women	and	children,	are	represented	
in	 research	 in	order	 to	help	guide	scientific‐based	practice	 for	all	
societal	groups.17‐19	With	the	advent	of	perinatal	research	centres,	
each	year	more	trials	specific	 to	pregnant	women	are	developed,	
funded	 and	 conducted	 globally.20,21	 Literature	 is	 sparse	 in	 rela‐
tion	to	women's	willingness	to	take	part	 in	clinical	research	while	
pregnant.22‐24	In	addition,	lack	of	experience	in	including	pregnant	
women	 in	 trials	may	 lead	 to	 poor	 trial	 design	 and	 hence	 recruit‐
ment	difficulties.25‐27	It	is	well	documented	that	under‐recruitment	
is	often	an	issue	in	RCTS,	with	a	third	not	reaching	target	and	over	
50%	 requiring	 extensions.28	 Given	 that	 we	 are	 involved	 in	 con‐
ducting	an	RCT	of	an	interventional	diagnostic	test	on	a	pregnant	
population,	we	determined	we	had	a	unique	opportunity	to	explore	
pregnant	women's	views	of	participation	in	research,	within	a	clin‐
ical	trial.	Our	aim	was	to	explore	women's	experience	on	being	in‐
volved	 in	a	clinical	trial,	specifically	a	randomized	controlled	trial,	
while	pregnant.
2  | METHODS
This	 qualitative	 study	was	 nested	within	 a	 randomized	 controlled	
trial	of	a	point‐of‐care	diagnostic	test	(NCT	02881073)	for	pre‐term	
preeclampsia	in	Ireland.	We	first	describe	the	PARROT	Ireland	RCT	
and	then	describe	the	nested	qualitative	study.
2.1 | PARROT Ireland
PARROT	Ireland	was	a	multi‐site,	national	study	recruiting	women	
in	 the	 seven	 largest	 maternity	 units	 in	 Ireland,	 from	 29th	 June	
2017	 until	 26th	 April	 2019.	 The	 trial	 aimed	 to	 examine	whether	
the	addition	of	point‐of‐care	Placental	Growth	Factor	(PlGF)	test‐
ing	 to	 routine	 clinical	 care	 improved	both	maternal	 and	neonatal	
outcomes	 for	 women	 with	 a	 pre‐term	 singleton	 pregnancy,	 and	
signs	 or	 symptoms	of	 preeclampsia	 or	 placental	 dysfunction.29	 If	
an	eligible	pregnant	woman	consented	to	participate,	she	was	ran‐
domized	 to	 either	 control	 (routine	 care)	 or	 intervention	 (immedi‐
ate	additional	PlGF	testing)	based	on	the	current	randomization	of	
her	hospital	at	 the	timepoint	of	her	enrolment.	As	randomization	
was	unblinded,	both	the	participant	and	her	clinical	care	team	were	
aware	of	her	allocation	and	her	PlGF	result	if	she	was	randomized	
to	the	intervention.
2.2 | Nested qualitative study design
Participants	at	a	single	study	site	were	given	the	opportunity	to	par‐
ticipate	 in	 the	 qualitative	 study.	We	 employed	 a	 qualitative	 study	
design,	using	semi‐structured	interviews,	to	explore	women's	views,	
experience	and	beliefs	regarding	pregnancy	research.	A	semi‐struc‐
tured	topic	guide	was	developed	based	on	existing	literature.26,30‐33 
Qualitative	 research	 has	 been	 utilized	 for	 many	 years	 to	 provide	
insight	 into	problems,	help	develop	hypotheses	and	to	gain	an	un‐
derstanding	 of	 underlying	 reasons,	 opinions	 and	 motivations.34 
Interviews	rather	than	surveys	were	employed	as	they	facilitated	a	
relationship	of	trust	to	be	established	between	the	researcher	and	
participant.35	 One‐to‐one	 interviews	 allowed	 for	 an	 environment	
where	each	participant	was	able	to	express	themselves	more	openly	
than	perhaps	a	focus	group	may	have	allowed.36
2.3 | Recruitment
Purposive	 sampling	 of	 women	 who	 had	 recently	 completed	 the	
PARROT	RCT	was	employed	to	ensure	each	arm	of	 the	trial	was	
represented.	 Due	 to	 the	 stepped	wedge	 design	 of	 the	 trial,	 the	
interval	from	recruitment	until	the	interview	was	longer	for	those	
recruited	in	the	control	than	the	intervention.	These	women	had	
previously	consented	to	be	approached	about	further	trial‐related	
research.	Each	received	a	patient	information	leaflet	and	invitation	
to	participate	by	post.	Women	who	agreed	to	participate	attended	
to	the	maternity	hospital	 in‐person	 (n	=	16)	or	were	 interviewed	
by	 telephone	 (n	 =	 3)	 if	 in‐person	 attendance	 was	 not	 feasible.	
Informed	written	 consent	was	 obtained,	 and	 the	 interview	 pro‐
cess	took	approximately	30	minutes.	 Interviews	were	conducted	
over	a	three‐month	period	(September	2018‐December	2018)	by	
DHR	until	data	saturation	was	reached.	At	the	time	of	interview,	
the	 PARROT	 Ireland	 trial	 was	 on‐going	 so	 results	 were	 not	 yet	
available	to	participants	or	researchers.	Eighteen	of	the	nineteen	
interviews	were	recorded	digitally	and	transcribed	verbatim.	The	
one	woman	that	did	not	wish	to	be	digitally	recorded	gave	consent	
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for	note	taking	by	the	researcher	throughout	the	interview.	These	
notes	were	used	to	inform	the	analysis.
2.4 | Analysis
Interview	 transcripts	 were	 thematically	 analysed	 by	 DHR	 and	
SM.37,38	In	the	initial	analysis,	each	line	of	the	transcript	was	coded	
into	categories.	The	categories	were	then	reviewed	and	refined,	and	
themes	were	developed.	These	key	themes	were	then	presented	and	
agreed	upon	by	the	entire	research	team.
3  | RESULTS
Nineteen	 women	 were	 interviewed,	 ten	 of	 whom	 had	 been	 rand‐
omized	to	the	control	arm	and	nine	who	had	been	randomized	to	the	
intervention	arm	of	the	trial.	Time	from	completion	of	study	ranged	
from	6	to	15	months	at	the	time	of	the	 interview.	All	women	inter‐
viewed	were	Caucasian,	 age	 ranged	 from	24	 to	42	years,	 and	52%	
were	nulliparous	prior	to	their	recent	pregnancy.	Four	themes	were	
identified	as	follows:	(a)	Understanding	of	preeclampsia,	(b)	Motivators	
for	clinical	 trial	participation,	 (c)	Barriers	 to	decision	making	and	 (d)	
Influence	of	PARROT	Ireland	on	pregnancy	experience.	Direct	quota‐
tions	from	the	women,	presented	in‐text,	are	used	to	illustrate	these	
themes.
3.1 | Understanding of preeclampsia
Women	were	recruited	to	the	PARROT	Ireland	trial	on	the	basis	that	
they	were	exhibiting	signs	or	symptoms	of	pre‐term	preeclampsia	in	
their	pregnancy.	Some	women	were	diagnosed	with	preeclampsia.	
They	described	the	significant	 impact	this	had	on	their	pregnancy,	
emphasizing	how	it	took	over	their	lives	leaving	them	with	a	lack	of	
control	and	autonomy.
…suddenly	 I	was	 in	 hospital	 and	 I	 didn't	 leave	 for	 a	
month.	I	had	loads	of	planning	to	do	and	my	mat	leave	
was	happening	the	next	day	and	just	small	things	that	
were	kind	of	taken	away	in	a	sense,	putting	the	nap‐
pies	in	where	I	wanted	to	put	them	and	the	vests	and	
washing	 them	 and	 all	 those	 little	 preparation	 stuff	
that	I	was	kind	of	looking	forward	to	
P8
Most	 of	 those	 interviewed	 reported	 only	 having	 vaguely	 heard	
of	the	condition	prior	to	their	pregnancy	with	friends	or	social	media	
being	the	main	source	of	their	knowledge.	As	most	of	the	participants	
were	nulliparous	women	at	the	beginning	of	their	pregnancies,	these	
women	did	not	feel	that	preeclampsia	was	of	concern	to	them.
It	didn’t	really	affect	me,	it	wasn’t	anything	to	do	with	
me 
P3
Most	 of	 those	 interviewed	 were	 not	 aware	 of	 risk	 factors	 for	
preeclampsia	and	had	misconceptions	about	who	might	develop	pre‐
eclampsia.	Women	commonly	stated	that	they	were	shocked	when	the	
possibility	of	preeclampsia	arose	later	in	their	pregnancy.
Like	 I	 thought	 it	was	 something	 kind	 of	 third	world	
people	got	
P7
I	would	have	heard	of	 it,	but	 I	wouldn’t	have	known	
much	about	it	
P15
Before	 being	 pregnant	 I	 don’t	 think…	 maybe	 I	 had	
heard	 the	 word	 pre‐eclampsia,	 but	 I	 definitely	
wouldn’t	have	known	any	specific	information	
P17
Those	who	had	been	pregnant	previously,	especially	those	previ‐
ously	investigated	for	preeclampsia,	had	better	knowledge	of	the	risks,	
symptoms	and	potential	consequences	of	the	condition.
I	 definitely	 thought	 that	 you	 were	 overweight	 and	
unfit	and	like	you'd	brought	it	on	yourself	kind	of	thing	
P9
I	was	definitely	more	aware	of	 it,	 because	 they	had	
mentioned	it’s	a	possibility	or	that	it	is	more	probable	
the	second	time	round.	So,	I	would	have	been	aware	
of	at	least	the	symptoms	of	it	and	watching	out	more	
in	the	second	pregnancy	
P17
When	subsequently	informed	that	they	required	investigation	for	
preeclampsia,	women	were	eager	 for	 simple,	 clear,	 concise	 informa‐
tion	about	the	condition	from	a	reliable	source.	Some	felt	they	got	the	
necessary	information	from	their	clinical	care	team.	Others	searched	
for	the	information	themselves,	usually	using	online	sources,	and	often	
felt	overwhelmed	at	the	vast	amount	and	varied	quality	of	information	
available.
You	don't	know	where	 to	 look	regarding	wanting	 to	
get	correct	information	because	there's	so	much	now	
online 
P8
3.2 | Motivators for participation in clinical research
Despite	 limited	previous	experience	with	participation	in	research,	
especially	medical	 research,	 the	women	had	 extensive	 knowledge	
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regarding	research.	All	were	convinced	about	the	merit	and	impor‐
tance	of	research,	especially	in	pregnancy,	for	increasing	knowledge	
of	conditions	and	improving	future	clinical	care.
I	 just	 think	 information	 is	 power	 and	 the	 numbers	
don't	 lie	 and	 if	 you	 have	 information,	 you	 can	 do	
something	
P9
I	felt	like	whatever	we	could	do	it	would	be	a	benefit,	
so	I	was	happy	to	participate	to	be	honest	
P13
Almost	all	of	those	interviewed	reported	it	was	a	straightforward	
decision	to	take	part	in	PARROT	Ireland,	and	that	it	did	not	require	a	lot	
of	time	for	consideration	nor	involve	discussion	with	others.
…as	far	as	I	was	concerned	it	was	my	body	and	they	
didn’t	really	have	a	say	
P2
The	study	was	quite	easy‐going,	you	know,	it's	a	blood	
test	or	no	blood	test	and	then	a	questionnaire,	so	that	
was	no	real	decision	on	my	part	in	that	it	was	handy	
enough	
P13
The	women	reported	altruism	and	the	potential	to	help	others	in	
the	future	as	a	key	motivator	for	participation.	Many	felt	their	contri‐
bution	was	essentially	‘paying	it	forward’	for	the	knowledge	that	could	
be	garnered	from	their	current	pregnancies	in	order	to	benefit	those	in	
the	future.	A	second	key	motivator	to	participate	was	a	lack	of	burden	
associated	with	participation	in	the	PARROT	trial.	Even	though	women	
reported	they	would	be	happy	to	give	extra	time	or	attend	for	extra	
appointments	if	required	for	research	purposes,	one	of	the	main	fac‐
tors	was	how	straightforward	it	was	to	take	part	in	the	PARROT	trial.
other	 people	 being	 involved	 in	 research	 previously	
surely	helped	me	when	I	was	pregnant	
P3
the	fact	 that	 it	was	so	simple….you	could	say	yes	or	
no…and	then	you	have	a	blood	test	or	you	didn’t	and	
then	there	was	no	extra	travel	or	filling	out	huge	sur‐
veys	or	anything	like	that	
P17
The	 potential	 of	 participation	 facilitating	 an	 opportunity	
of	 an	 earlier	 diagnosis,	 or	 identification	 of	 a	 problem,	 also	 influ‐
enced	women's	decision	 to	enrol.	Women	 felt	 that	by	being	part	
of	 the	 study	 they	might	 know	 sooner	 than	 others	 if	 they	 devel‐
oped	 a	 pregnancy	 complication.	 The	 demeanour	 of	 the	 PARROT	
researcher	was	also	reported	to	be	an	important	factor	in	their	de‐
cision	to	take	part.	Women	discussed	the	researcher's	style	of	ap‐
proaching	eligible	women	remarking	that	the	researcher	was	kind	
and	friendly,	made	them	feel	at	ease,	explained	the	study	in	clear	
simple	terms,	all	without	rushing	or	pressurizing	women	in	any	way.
she	couldn’t	have	been	nicer,	she	really	couldn’t…had	
she	not	been	so	sensitive	and	understanding	I	possi‐
bly	wouldn’t	have	you	know	
P5
It	was	completely	up	to	me	and	I	didn’t	feel	at	all	under	
pressure.	I	mean	I	could	have	just	left	it.	I	remember	
there	was	a	window	just	next	to	me	so	I	could	have	
just	left	it	on	the	window	sill	and	you	know,	nothing	
would	have	ever	come	of	it	
P17
Women	reported	being	positively	influenced	to	take	part	if	they	
heard	about	the	trial	from	their	treating	clinician.	Most	believed	the	
trial	would	not	have	been	suggested	to	them	unless	 it	was	useful	
and	would	be	beneficial	 to	 them.	They	also	 reported	being	more	
likely	to	take	part	if	they	recognized	the	name	of	one	of	the	princi‐
pal	investigators	(PI)	of	the	study.	The	women	discussed	how	these	
PIs	are	senior	consultants	who	are	well	respected	clinically	and	are	
highly	sought	after	for	private	obstetric	antenatal	care	locally.
I	think	that	was	less	pressure	in	a	sense,	because	you	
know	when	 the	 researcher	 approached	me	 directly,	
it’s	 kind	 of	 my	 responsibility	 “do	 you	 want	 to	 take	
part?”	whereas	when	 it	 comes	 from	you	 know	your	
consultant	it’s	an	easier	step	to	take	then	
P5
3.3 | Barriers to decision making
The	 main	 deterrent	 to	 participation	 in	 clinical	 research	 identified	
by	 the	 group	was	 risk.	 The	 group	 reported	 being	 highly	 reluctant	
to	take	part	in	any	research	should	they	perceive	it	as	being	poten‐
tially	 harmful	 to	 the	developing	 foetus.	 Taking	 a	medication	while	
pregnant,	as	part	of	a	research	trial,	was	an	example	of	what	women	
would	consider	risky.	Most	would	be	very	reluctant	to	take	part	in	
such	a	trial	and	admitted	it	would	require	very	careful	consideration	
and	discussion	with	their	partner	if	they	were	approached	in	the	fu‐
ture	about	such	a	research	study.
I'd	be	very	slow,	I'd	have	to	really	think	about	it,	purely	
because	it's	somebody	else's	life	you're	putting	on	the	
line,	not	just	your	own,	it’s	somebody	else's	future	
P7
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The	potential	 requirement	 for	 blood	 tests	 from	 the	woman	 as	
part	of	a	clinical	study	was	not	found	to	be	a	deterrent	among	the	
group;	however,	 if	blood	sampling	was	required	from	the	baby	fol‐
lowing	delivery,	this	would	be	considered	a	deterrent.	Any	test	that	
was	 invasive,	 and	 potentially	 would	 cause	 distress	 or	 pain	 to	 the	
baby,	that	was	not	required	outside	of	a	research	setting	would	not	
be well received.
You	don't	want	to	be	the	guinea	pig	and	you	certainly	
don't	 want	 the	 baby	 to	 be	 the	 guinea	 pig	 either…	
you're	like	well	can	some	people	in	some	other	coun‐
tries	sign	up	 first	and	see	what	 the	outcome	 is.	You	
always	want	somebody	else	 to	stick	 their	 toe	 in	 the	
water	first	
P9
The	clinical	situation	of	the	individual	woman,	at	the	time	point	
when	she	is	approached	to	participate	in	a	trial,	was	flagged	by	those	
interviewed	as	 important	 to	 consider.	Many	participants	 reported	
that	 if	they	had	recently	received	sensitive	or	distressing	 informa‐
tion	or	were	 currently	 experiencing	 serious	 complications	 in	 their	
pregnancy;	they	may	have	been	less	willing	to	take	part	in	the	trial.	
The	women	 interviewed	mentioned	that	the	 language	used	by	re‐
searchers	when	approaching	eligible	pregnant	women	is	important	
to	consider.	Using	complicated	words	and	medical	 jargon	could	be	
frightening	for	some	women	and	many	stated	it	would	sway	them	
against	participation.
Like	I	do	think	it	is	very	dependent	on	you	know	the	
news	that	you	have	been	given,	like	if	you	have	been	
given	 very	 sensitive	 news,	 you	might	 feel	 like,	 why	
should	I	be….	the	guinea	pig	to	help	future	cases	
P5
I	think	any	pregnant	woman	would	happily	take	part,	
I	think	the	only	time	that	someone	might	not	want	to	
do	it	is	if	they	are	facing	a	crisis,	and	they	are	in	a	bit	
of	a	fog	and	they	can’t	really	think	
P2
I	think	the	only	thing	that	would	turn	people	off	is	say‐
ing	 its	medical	 research	–that	 can	 be	 scary.	Maybe,	
say	its	more	for	women’s	health	
P4
3.4 | Influence of PARROT on pregnancy experience
When	approached	for	further	interview,	all	those	who	agreed	to	take	
part	reported	recalling	the	trial	and	their	agreement	to	take	part.	The	
name	of	the	trial,	PARROT,	was	found	to	be	memorable.	Most	were	
uncertain	as	to	why	a	trial	concerning	pregnant	women	and	preec‐
lampsia	had	used	an	acronym	representing	a	bird.	Some	understood	
this	was	 an	 abbreviation	 for	 a	 longer	name.	Nobody	 reported	 the	
name	to	have	negative	connotations,	but	some	did	mention	that	 if	
it	had	mentioned	a	baby	in	the	title,	it	may	have	been	more	inviting.
no	I	remember	the	name	because	I	have	a	parrot!	So,	if	
it	had	been	another	name	…	but	I	remember	this	
P6
It	did	cross	my	mind…”why	parrot”?	but	I	didn’t	think	
too	 much	 about	 it	 really.	 I	 remembered	 it	 straight	
away	so	maybe	the	name	was	good	
P14
All	enrolled	participants	in	PARROT	Ireland	were	asked	to	com‐
plete	 a	 five‐page	paper	Quality	 of	 Life	 questionnaire	 at	 the	 time	
point	 of	 their	 enrolment	 and	 again	 prior	 to	 their	 discharge	 from	
hospital	postnatally.	When	asked	about	their	thoughts	on	the	ques‐
tionnaire,	most	respondents	had	little	memory	of	it	and	did	not	re‐
port	 it	as	being	off‐putting	or	time‐consuming.	Some	commented	
that	they	were	a	welcome	distraction	while	waiting	in	a	busy	ante‐
natal	clinic	and	allowed	them	time	to	reflect	on	their	current	self.
The	 researcher	 …	 she	 was	 dropping	 the	 follow‐up	
questionnaire,	 so	 she	could	know	 if	 I	needed	 to	get	
on	to	somebody	
P13
One	thing	I	did	 like	about	 it	was	 it	makes	you	think,	
it	made	me	think	about	where	I	was	at	in	the	weeks	
after	having	my	baby,	it	gives	you	time	to	think	what	
level	of	anxiety	am	I	now,	so	that	was	nice,	that	was	a	
really	good	benefit	of	it	
P8
The	majority	of	participants	were	aware	of	the	concept	of	ran‐
domization	in	a	research	setting	and	recognized	the	importance	of	
assigning	participants	to	groups	in	order	to	be	able	to	examine	the	
outcomes	when	evaluating	a	new	test,	etc
I	guess	controls	are	important	I	suppose,	to	some	ex‐
tent	you	know,	you	need	a	certain	amount	of	people	
to	take	part	in	order	to	get	a	certain	level	of	statistics,	
that	you	need	you	know	
P10
While	 I	 would	 still	 like	 to	 be	 part	 of	 the	 group	 of	
people	that	get	the	test,	for	research	to	develop	and	
everything	they	need	people	on	the	other	side	of	it,	
so	I	suppose	that	I	would	accept	the	plan	whatever	
it	was	
P12
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A	distinct	difference	was	expressed	between	those	in	the	control	
and	those	in	the	intervention	regarding	the	overall	experience	of	the	
trial	on	their	pregnancy.	Those	from	the	control	group	had	a	poorer	
recollection	of	what	the	purpose	of	the	trial	was	and	that	a	blood	test	
was	offered	to	half	the	cohort.	The	women	recruited	to	the	control	arm	
felt	that	the	trial	did	not	impact	on	or	influence	their	pregnancy	in	any	
way	but	were	still	happy	to	have	taken	part.
It	 was	 really	 personable,	 it	 actually	 wasn’t	 like	 we	
were	just	another	case	number.	If	anything	it	brought	
me	 on	 sense	 of…somethings	 going	 right.	 Like	 there	
was	never	anything	bad	 to	come	out	of	 the	 trial	 for	
me,	 like	 worst	 case	 scenario	 you	 got	 nothing,	 you	
were	 just	 like	you	were	when	you	started.	 it	was	all	
beneficial	in	one	form	or	another	depending	on	what	
way	you	looked	at	it	
P2
I	suppose,	all	 I	was	thinking	of	was	 if	 it	will	help	me	
or	help	other	people	I	will.	But	to	be	honest	informa‐
tion	 probably	went	 a	 little	 over	my	 head,	 I	 actually	
can’t	tell	you	now	what	the	Parrot	Study	is,	and	that	
….through	no	fault	of	anybody,	but	I	personally	had	so	
much	going	on	
P16
Those	who	were	in	the	intervention	arm	had	a	better	recollection	
of	the	purpose	of	the	trial	and	overwhelmingly	felt	being	enrolled	onto	
the	trial	was	beneficial	to	their	pregnancy.	They	felt	that	knowledge	of	
the	PlGF	result,	whether	it	was	normal	or	abnormal,	was	useful	to	the	
clinicians	 caring	 for	 them	and	positively	 influenced	 their	 pregnancy.	
They	also	felt	they	received	extra	care	from	their	clinicians	due	to	their	
involvement	in	the	trial	and	having	had	the	extra	blood	test	performed.
I	just	felt	that	everyone	was	giving	the	best	care	and	
all	of	this	research	and	all	of	this	information	was	for	
my	 baby’s	 good	 so	 I	 thought	 it	 was	 a	 very	 positive	
thing	
P18
I	thought	it	was	very	good,	to	be	honest.	It	was	hands‐
on	 like,	 you	 know.	 I	 don’t	 remember	 ever	 a	 doctor	
ringing	me	 like,	so….I	was	happy	with	that.	 I	 think	 it	
put	a	rush	on	me	being	monitored,	if	I’m	being	honest,	
it	was	definitely	beneficial	
P18
4  | DISCUSSION
This	 qualitative	 study	 brings	 together	 insight	 into	 women's	 deci‐
sion	making	regarding	participation	in	an	interventional	clinical	trial	
during	pregnancy.	We	identified	that	pregnant	women	are	aware	of	
the	importance	of	conducting	research	and	are	interested	in	taking	
part,	provided	participation	does	not	put	their	unborn	baby	at	any	
risk.	We	found	there	was	 limited	background	knowledge	of	preec‐
lampsia	 among	 the	 group	 and	women	wanted	 information	on	 this	
condition	to	be	clear,	concise	and	provided	by	a	reliable	source.	 In	
our	 study,	 those	 randomized	 to	 the	 intervention	 felt	 participation	
in	 the	 trial	 directly	 benefited	 their	 pregnancy,	with	 the	 additional	
test	providing	valuable	information	on	placental	functioning	and	the	
perception	of	increased	care	from	clinicians.	On	reviewing	the	litera‐
ture,	we	 identified	 limited	numbers	of	 previous	 studies	 examining	
women's	experience	of	participation	in	a	RCT	while	pregnant.30‐33,39 
These	 RCTs	 vary	 in	 terms	 of	 design	 and	methodology,	 frequently	
involved	administration	of	a	medicinal	product	or	a	placebo.	Given	
that	 our	 RCT	 employed	 a	 diagnostic	 test	 as	 the	 intervention,	 we	
identified	a	novel	opportunity	 to	gain	 insight	and	add	new	knowl‐
edge	to	this	under‐examined	area.
Participants	of	our	nested	study	reported	both	altruism	and	the	
potential	of	personnel	benefit	 to	be	key	motivators	 in	 their	enrol‐
ment	in	PARROT	Ireland.	The	prospect	of	an	additional	blood	test,	
with	its	potential	of	earlier	identification	and	diagnosis	of	a	clinical	
complication,	was	an	incentive	for	our	study.	Others	have	similarly	
reported	a	sense	of	civic	duty,	 the	opportunity	to	help	others	and	
the	possibility	of	an	improved	outcome	for	their	baby	to	be	driving	
forces	behind	participation.30,32	A	Brazilian	group	reported	the	main	
motivator	to	comprise	access	to	free	medicine	and	an	opportunity	to	
engage	with	health‐care	providers.31	This	highlights	that	in	countries	
where	health	care	during	pregnancy	is	not	publicly	available,	partic‐
ipation	in	clinical	research	may	be	the	only	option	those	with	limited	
financial	means	have	in	order	to	access	medical	care.	In	such	cases,	
governance	of	 research	 trials	must	 be	 closely	 regulated	 to	 ensure	
this	vulnerable	group	are	not	exploited.
Respondents	 in	 our	 study	 reported	 being	more	 likely	 to	 take	
part	in	the	trial	if	it	was	mentioned	to	them	by	their	treating	clinician	
or	 a	member	of	 the	medical	 team.	Endorsement	of	 the	 trial	 from	
medical	personnel	appears	to	validate	a	study	for	patients.	Similarly	
a	 lack	of	 interest	or	 support	 from	 local	 clinical	 staff	has	been	 re‐
ported	as	 a	barrier	 to	participation.26	Accurate	 knowledge	by	 cli‐
nicians	of	on‐going	trials	in	their	unit	and	the	vocalization	of	their	
support	is	crucial	in	promoting	participation	of	pregnant	women	in	
future	trials.
This	 nested	 study	 identified	 that	 the	 main	 barrier	 preventing	
participation	of	 pregnant	women	 in	 clinical	 research	 is	 the	poten‐
tial	of	causing	harm	to	the	baby.	Others	have	also	found	pregnant	
women	 to	 be	 risk	 adverse,	 with	 apprehension	 and	 risk	 limitation	
being	 common	barriers	 prohibiting	 participation.26,32	Clinical	 trials	
require	sponsorship,	insurance	and	undergo	rigorous	review	by	na‐
tional	 ethical	 committees	prior	 to	 their	 commencement.	On‐going	
clinical	trials	are	vigilantly	monitored	by	stakeholders,	to	ensure	any	
trends	in	adverse	events	are	quickly	detected	and	can	be	acted	upon	
with	 possible	 cessation	of	 the	 trial	 if	 necessary.11,21,40	Changing	 a	
pregnant	woman's	perception	of	risk	is	key.	Education,	through	the	
information	and	explanation	provided	by	researchers,	is	paramount.	
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Adequate	training	of	researchers	and	clinicians,	to	maximize	this	skill	
set,	should	be	prioritized	for	future	studies.
This	study	revealed	that	the	decision	to	take	part	in	the	PARROT	
Ireland	trial	was	made	independently	by	the	pregnant	woman	herself,	
without	any	consultation	with	her	partner,	friends	or	family.	Similar	
findings	 were	 reported	 in	 the	 QUOTE	 study,33	 while	 in	 contrast	
the	RIPE	study	 32	 reported	equal	 involvement	of	both	 the	women	
and	her	partner	 in	 the	decision	to	 take	part	 in	an	RCT.	Both	RCTs	
involved	 taking	 a	medication	while	 pregnant;	 however,	 in	QUOTE	
women	had	preeclampsia	when	enrolled,	whereas	 in	RIPE	healthy	
pregnant	women	were	 recruited.	This	 finding	highlights	 trials	 that	
involve	taking	a	medication	while	pregnant,	especially	 if	 recruiting	
healthy	 pregnant	 volunteers,	 likely	 require	 a	 longer	 time	 interval	
from	first	approach	by	researchers	until	signing	consent,	to	facilitate	
shared	decision	making.
Women	 reported	 feeling	 well	 informed	 about	 the	 PARROT	
Ireland	trial	prior	to	signing	the	consent	and	later	had	a	good	un‐
derstanding	of	the	trial	when	interviewed.	Respondents	reported	
that	the	timing	and	setting	of	the	researcher's	approach	were	ap‐
propriate	 and	 the	 language	used	was	understandable	 and	unam‐
biguous.	 In	 contrast,	 participants	 of	 both	 the	MAGPIE41	 and	 the	
ORACLE42	RCTs	reported	confusion	when	the	trial	was	initially	ex‐
plained	to	them.	They	did	not	fully	understand	that	randomization	
meant	 they	might	not	 receive	 the	 intervention	and	subsequently	
had	limited	knowledge	and	recall	about	the	trials.30,33	This	differ‐
ence	may	 be	 attributable	 to	 the	 clinical	 situation	 of	 the	women	
at	 the	 time	 of	 recruitment.	 For	 PARROT	 Ireland,	 eligible	women	
were	 approached	 in	 a	 variety	 of	 clinical	 settings,	 antenatal	 clin‐
ics,	wards,	assessment	units,	all	while	undergoing	routine	assess‐
ments.	Both	the	MAGPIE	and	ORACLE	trials	 recruited	women	 in	
Labour	Ward/High	Dependency	Ward,	 either	 in	 pre‐term	 labour	
or	close	to	indicated	emergency	delivery.	Given	the	complexity	of	
these	clinical	situations,	it	 is	plausible	that	women	may	feel	over‐
whelmed	 and	 unable	 to	 clearly	 assimilate	 information	 provided	
about	 a	 research	 study.	Designing	 future	 trials	with	 recruitment	
focused	in	non‐emergent	situations	may	provide	a	solution	to	this,	
and	 ensure	 patient	 vulnerability	 is	 not	 exploited.	 An	 alternative	
could	be	to	employ	the	use	of	a	delayed	consent	process	for	labour	
ward‐based	trials.43	This	approach	has	been	employed	in	trials	of	
critically	 ill	 patients,	 is	well	 described	 and	has	 been	 found	 to	 be	
acceptable	to	patients.44
The	women	in	our	study	randomized	to	the	control	did	not	re‐
port	negative	experiences.	Although	they	felt	the	trial	had	no	direct	
impact	on	their	pregnancy,	they	were	still	happy	to	have	taken	part.	
In	contrast	to	our	results,	others	have	reported	randomization	to	the	
control	of	an	RCT	perceived	as	being	disadvantageous.32	A	 loss	of	
equipoise	on	the	subject	under	investigation	may	be	one	explanation	
or	 equally	 a	 familiarity	 of	 the	 intervention	 among	 the	 population.	
Prior	to	randomization	in	a	study,	if	participants	have	strong	favour‐
able	personal	opinions	on	the	product	being	investigated,	it	may	lead	
to	disappointment	and	disillusionment	if	they	then	are	randomized	
to	the	control.	This	highlights	the	need	for	education	of	eligible	par‐
ticipants	 by	 researchers	 on	 the	 purpose	 and	 importance	 of	 both	
arms	of	a	RCT.	It	also	highlights	the	impact	background	knowledge	
of	the	topic	under	review	in	the	eligible	population	may	have	on	their	
willingness	to	participate	and	needs	to	be	considered	by	researchers	
when	planning	future	studies.
The	 women	 we	 interviewed	 are	 likely	 to	 be	 highly	 moti‐
vated	 and	 interested	 in	 research	 as	 they	 not	 only	 took	 part	 in	
the	trial	during	their	pregnancy,	but	also	agreed	to	participate	in	
the	qualitative	 study.	 Ideally,	we	would	 have	 interviewed	 those	
who	declined	to	take	part	in	the	trial	also,	as	this	would	have	bet‐
ter	 elicited	 the	 barriers	 to	 research	 participation	 in	 pregnancy.	
However,	as	per	Good	Clinical	Practice	(GCP)45	and	General	Data	
Protection	Regulations	 (GDPR)46	we	did	not	retain	any	 informa‐
tion	 on	 eligible	 women	 who	 were	 approached	 but	 declined	 to	
participate	 in	 the	 trial,	 thus	 contacting	 them	 for	 this	 study	was	
not	feasible.	Strengths	of	our	study	include	in‐person	interviews,	
facilitating	a	more	personal	relationship	between	the	researcher	
and	 participant	 as	 well	 as	 close	 proximity	 of	 interview	 to	 time	
of	participation,	which	greatly	aided	participants	recall.	Uniquely,	
the	 PARROT	 Ireland	 RCT	was	 not	 blinded;	 hence,	 even	 though	
the	trial	has	not	yet	published,	women	subsequently	interviewed	
were	aware	of	their	randomization	and,	for	those	in	the	interven‐
tion,	knew	their	PlGF	result.
Our	findings	correlate	well	with	those	from	a	recent	systematic	
review	examining	the	facilitators	and	barriers	to	pregnant	women's	
participation	in	research.39	It	reported	altruism	and	the	potential	to	
contribute	to	science	to	rank	highly	as	motivators	to	women's	par‐
ticipation.	 The	 potential	 for	 personal	 benefit,	 through	 increased	
surveillance	 or	 earlier	 detection	 of	medical	 conditions,	was	 also	 a	
commonly	reported	motivator.	Similar	to	our	nested	study,	the	sys‐
tematic	 review	 reported	pregnant	women	 to	 be	 risk	 adverse	with	
the	potential	 requirement	of	 taking	a	medication	while	pregnant	a	
major	barrier	to	participation.	Unlike	our	study,	the	review	reported	
personnel	 inconvenience	as	a	barrier	 to	participation	among	preg‐
nant	women.	This	difference	may	potentially	be	explained	by	the	de‐
sign	of	our	trial,	with	no	on‐going	assessments	or	repeat	attendance	
required	 it	 was	 well	 received	 by	 participants.	 Another	 difference	
between	the	two	studies	was	an	underlying	distrust	of	researchers	
identified	by	the	authors	of	the	systematic	review.	This	difference	
may	possibly	be	explained	by	the	demeanour	and	approach	adopted	
by	 the	 research	midwife	of	our	 study.	Her	 candour	and	non‐pres‐
surizing	 approach	 were	 frequently	 positively	 commented	 on	 by	
participants.
5  | CONCLUSION
This	study	highlights	that	pregnant	women	are	aware	of	the	impor‐
tance	of	research	and	are	generally	interested	and	positively	inclined	
to	participate.	 It	 identifies	 that	 the	context,	purpose	and	potential	
risk	 of	 any	 research	 are	 the	most	 important	 considerations	 to	 an	
eligible	pregnant	woman.	The	approach	and	explanation	adopted	by	
both	researchers	and	clinicians	are	paramount	in	aiding	women's	un‐
derstanding	of	a	research	trial.	This	information	may	aid	the	design	
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and	conduct	of	future	studies,	thereby	increasing	their	acceptability	
for	pregnant	women.
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